Korean pharmaceutical firms challenge Pfizer's Norvasc

Published: 2004-06-30 07:00:00

Updated: 2004-06-30 07:00:00

Korean major pharmaceutical markers are set to challenge Pfizer's current lead in the domestic amlodipine market by strategically launching their novel amlopdipine salts for sales boost, according to industry sources recently.

Following their products' approval from the Korea Food and Drug Adm...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK